ABZA.L

Abzena Plc
Abzena PLC - Result of Annual General Meeting
17th September 2018, 11:55
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9951A
Abzena PLC
17 September 2018
 

Abzena plc

 

Result of Annual General Meeting

 

Cambridge, UK, 17 September 2018: Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, announces that at its Annual General Meeting held today at 10:00am at the offices of Pinsent Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES, all resolutions were duly passed.

 

Details of the votes received in relation to each of the resolutions are as follows:

 

Resol

 

Vote For

% In favour

Votes Against

% Against

Votes Abstain

% Abstain

Total Votes

1

122,288,284

100

0

0

0

0

122,288,284

2

122,288,284

100

0

0

0

0

122,288,284

3

122,288,284

100

0

0

0

0

122,288,284

4

122,288,284

100

0

0

0

0

122,288,284

5

122,288,284

100

0

0

0

0

122,288,284

6

122,288,284

100

0

0

0

0

122,288,284

7

122,288,284

100

0

0

0

0

122,288,284

8

122,288,284

100

0

0

0

0

122,288,284

Percentage figures have been subject to rounding as considered appropriate.

 

The total number of ordinary shares of £0.002 each eligible to be voted at the Annual General Meeting was 214,220,399.

 

Enquiries:

 

Abzena Plc

John Burt (Chief Executive Officer) Julian Smith (Chief Financial Officer)

+44 1223 903498

 

 

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell
Ben Farrow

 

+44 20 7496 3000

Instinctif Partners

Melanie Toyne Sewell
Rozi Morris
Alex Shaw

+44 20 7457 2020

abzena@instinctif.com

 

 

Notes to Editors

 

About Abzena

 

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

 

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENA Inside products.

 

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

 

·     Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;

·     Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

·     Cell line development for the manufacture of recombinant proteins and antibodies;

·    Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

·    Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

·     Proprietary site-specific conjugation technologies and novel payloads for ADC development;

·     GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and

·     GMP analytical services for biopharmaceutical manufacturing projects.

 

For more information, please see www.abzena.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGFKODPDBKDBCD ]]>
TwitterFacebookLinkedIn